Compare Novavax Inc (NVAX) vs Consumer Staples Select Sector SPDR Fund (XLP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novavax Inc vs Consumer Staples Select Sector SPDR Fund — how do they compare? Novavax Inc trades at $8.12 (market cap $1.30B), while Consumer Staples Select Sector SPDR Fund trades at $84.01. The key difference: Consumer Staples Select Sector SPDR Fund is trading nearer its 52-week high, Novavax Inc nearer its low. Which is the better fit depends on your goals.
| NVAX | XLP | |
|---|---|---|
Market Cap | $1.30B | — |
Sector | Health | — |
52-Week High | $11.19 | $90.00 |
52-Week Low | $6.22 | $75.61 |
Enterprise Value | $800.50M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novavax (NVAX) trades at $8.08, down 1.64% on the day, with a bearish technical signal but strong recent earnings beats. The company reported $1.12B revenue in 2025 with a net income of $440.30M, though 2026 projections show a return to losses. Analyst consensus is bullish with a $14.00 price target, but negative shareholder equity and cash flow concerns persist.
Outlook remains mixed: strong valuation ratios and analyst support suggest upside potential, but negative cash flows, high liabilities, and projected 2026 losses pose significant risks. Investor sentiment is cautious amid recent stock declines and shareholder dissent highlighted in recent news.
XLP trades at $84.86, down 0.39% with a bullish technical signal from moving averages. The ETF shows strong analyst support with a 100% buy rating from 2 analysts and a 2.6% dividend yield. Recent news highlights XLP's defensive positioning amid market volatility, with consumer staples gaining favor as investors seek stability.
The outlook remains positive given XLP's defensive sector exposure and strong technical momentum. Key risks include sector concentration and macroeconomic pressures on consumer spending. With unanimous analyst bullishness and technical indicators supporting further upside, XLP presents a stable equity opportunity in uncertain markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →About Consumer Staples Select Sector SPDR Fund
In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes companies that have been identified as Consumer Staples companies by the GICS®. It is non-diversified.
Read more on XLP →
